Agree with GiveUsAChance.
Invex management was remarkable in Year 1, but ever since issuing themselves options, Investors have reason to be disappointed in Year 2.
Examples include:
1. Phase 2 was behind the timeline this year
2. Adverse regulatory advice from FDA was paired with a rushed conference call <1 hour after the announcement.
3. Haven't stuck to their estimated timelines for promoting a capital raising.
Maybe they're stretched thin - David M is at 4DS, Loveridge is running 4SC and Warren has left.
And that's why they put their Investor relations guy Duthy in charge as the new Executive Director.
Invex need to go back to the basics of good investor communication. Rather than an over-reliance on biotech analysts to write positive coverage by paying in large amounts of options - Scott Williams Fifty One Capital(1.25 mill) and Duthy(800K).
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
9.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $6.763M | |||
| Open | High | Low | Value | Volume |
| 0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 5 | 9.2¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 9.7¢ | 9000 | 1 |
View Market Depth
| Last trade - 16.21pm 15/07/2025 (20 minute delay) ? |
| IXC (ASX) Chart |
Day chart unavailable